BACKGROUND: Many patients with stage I-II pancreatic adenocarcinoma do not undergo resection. We hypothesized that (1) clinical staging underestimates nodal involvement, causing stage IIB to have a greater percent of resected patients and (2) this stage-shift causes discrepancies in observed survival. METHODS: The Surveillance, Epidemiology, and End Results (SEER) research database was used to evaluate cause-specific survival in patients with pancreatic adenocarcinoma from 2004-2012. Survival was compared using the log-rank test. Single-center data on 105 patients who underwent resection of pancreatic adenocarcinoma without neoadjuvant treatment were used to compare clinical and pathologic nodal staging. RESULTS: In SEER data, medium-term survival in stage IIB was superior to IB and IIA, with median cause-specific survival of 14, 9, and 11 months, respectively (P < .001). Seventy-two percent of stage IIB patients underwent resection vs 28% in IB and 36% in IIA (P < .001). In our institutional data, 12.4% of patients had clinical evidence of nodal involvement vs 69.5% by pathologic staging (P < .001). Among clinical stage IA-IIA patients, 71.6% had nodal involvement by pathologic staging. CONCLUSION: Both SEER and institutional data support substantial underestimation of nodal involvement by clinical staging. This finding has implications in decisions regarding neoadjuvant therapy and analysis of outcomes in the absence of pathologic staging.
BACKGROUND: Many patients with stage I-II pancreatic adenocarcinoma do not undergo resection. We hypothesized that (1) clinical staging underestimates nodal involvement, causing stage IIB to have a greater percent of resected patients and (2) this stage-shift causes discrepancies in observed survival. METHODS: The Surveillance, Epidemiology, and End Results (SEER) research database was used to evaluate cause-specific survival in patients with pancreatic adenocarcinoma from 2004-2012. Survival was compared using the log-rank test. Single-center data on 105 patients who underwent resection of pancreatic adenocarcinoma without neoadjuvant treatment were used to compare clinical and pathologic nodal staging. RESULTS: In SEER data, medium-term survival in stage IIB was superior to IB and IIA, with median cause-specific survival of 14, 9, and 11 months, respectively (P < .001). Seventy-two percent of stage IIB patients underwent resection vs 28% in IB and 36% in IIA (P < .001). In our institutional data, 12.4% of patients had clinical evidence of nodal involvement vs 69.5% by pathologic staging (P < .001). Among clinical stage IA-IIA patients, 71.6% had nodal involvement by pathologic staging. CONCLUSION: Both SEER and institutional data support substantial underestimation of nodal involvement by clinical staging. This finding has implications in decisions regarding neoadjuvant therapy and analysis of outcomes in the absence of pathologic staging.
Authors: Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang Journal: Cancer Date: 2011-07-06 Impact factor: 6.860
Authors: Karl Y Bilimoria; Andrew K Stewart; James S Tomlinson; E Greer Gay; Clifford Y Ko; Mark S Talamonti; David J Bentrem Journal: Ann Surg Oncol Date: 2007-09-27 Impact factor: 5.344
Authors: Olca Basturk; Burcu Saka; Serdar Balci; Lauren M Postlewait; Jessica Knight; Michael Goodman; David Kooby; Juan M Sarmiento; Bassel El-Rayes; Hyejeong Choi; Pelin Bagci; Alyssa Krasinskas; Brian Quigley; Michelle D Reid; Gizem Akkas; Shishir K Maithel; Volkan Adsay Journal: Ann Surg Oncol Date: 2015-09-11 Impact factor: 5.344
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Ann Surg Date: 2007-08 Impact factor: 12.969
Authors: Amir Fathi; Kathleen K Christians; Ben George; Paul S Ritch; Beth A Erickson; Parag Tolat; Fabian M Johnston; Douglas B Evans; Susan Tsai Journal: J Gastrointest Oncol Date: 2015-08
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Jamie Ritchey; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Cancer Date: 2007-08-15 Impact factor: 6.860
Authors: John R Bergquist; Carlos A Puig; Christopher R Shubert; Ryan T Groeschl; Elizabeth B Habermann; Michael L Kendrick; David M Nagorney; Rory L Smoot; Michael B Farnell; Mark J Truty Journal: J Am Coll Surg Date: 2016-02-23 Impact factor: 6.113
Authors: Madeleine P Strohl; Siavash Raigani; John B Ammori; Jeffrey M Hardacre; Julian A Kim Journal: Pancreas Date: 2016 May-Jun Impact factor: 3.327
Authors: Rachel L Dittmar; Suyu Liu; Mei Chee Tai; Kimal Rajapakshe; Ying Huang; Gary Longton; Christine DeCapite; Mark W Hurd; Pamela L Paris; Kimberly S Kirkwood; Cristian Coarfa; Anirban Maitra; Randall E Brand; Ann M Killary; Subrata Sen Journal: Cancer Prev Res (Phila) Date: 2021-04-23
Authors: Florian N Loch; Patrick Asbach; Matthias Haas; Hendrik Seeliger; Katharina Beyer; Christian Schineis; Claudius E Degro; Georgios A Margonis; Martin E Kreis; Carsten Kamphues Journal: World J Surg Oncol Date: 2020-08-18 Impact factor: 2.754